Overview

YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer

Status:
Terminated
Trial end date:
2004-02-01
Target enrollment:
0
Participant gender:
Male
Summary
The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Astellas Pharma US, Inc.
Treatments:
N-(6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl)-2-phenylethenesulfonamide